세계의 비침습적 산전 검사 시장 보고서 : 제품 유형별, 검사 유형별, 기술별, 방법별, 용도별, 최종 사용자별, 지역별(2024-2032년)

The global non-invasive prenatal testing market size reached US$ 4.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 14.0 Billion by 2032, exhibiting a growth rate (CAGR) of 14.6% during 2024-2032.

Non-invasive prenatal testing (NIPT) is a form of prenatal screening conducted on a pregnant woman's blood sample to detect the presence of fetal abnormalities. The test is primarily used to diagnose genetic disorders such as Down syndrome (or trisomy 21), Edwards syndrome (or trisomy 18), Patau syndrome (or trisomy 13) and Turner syndrome, by analyzing DNA fragments in the mother's blood. The procedure eliminates the need for various precarious and invasive procedures, such as chorionic villus sampling (CVS) and can be performed after nine weeks of pregnancy.

The growing prevalence of genetic disorders of the fetus is one of the key factors driving the market growth. Furthermore, technological advancements in the field of life sciences and healthcare industry is also providing a boost to the market. For instance, the development of DNA sequencing technologies, regenerative medicines and breakthroughs in molecular research have created immense possibilities to combat the chances of any serious disease at the primitive stage itself. Additionally, the increasing acceptance rate for prenatal testing, along with rising health consciousness and awareness regarding the benefits and significance of such testing among the masses, is also driving the market growth. Healthcare providers, as well as expecting parents, are adopting alternatives to diagnose other genetic disorders, including spina bifida, cleft palate, and sickle cell anemia, and treat them in the early stages of fetal development. Moreover, the shifting trend toward childbearing at high maternal age (35 years or older) is also positively impacting the market growth. Advancing maternal age can lead to numerous health complications, such as high blood pressure, reduced fertility, risk of miscarriage and increased risk of chromosomal anomalies in the fetus.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global non-invasive prenatal testing market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product type, test type, technology, method, application and end-user.

Breakup by Product Type:

Consumables

Instruments

Breakup by Test Type:

Materni 21

Harmony

Panaroma

Verifi

NIFTY

Others

Breakup by Technology:

NGS

WGS

Others

Breakup by Method:

Ultrasound Detection

Biochemical Screening Tests

Cell-Free DNA in Maternal Plasma Tests

Fetal Cells in Maternal Blood Tests

Others

Breakup by Application:

Trisomy

Microdeletion Syndrome

Others

Breakup by End-User:

Hospitals

Diagnostic Laboratories

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the top non invasive prenatal testing companies key players being Agilent Technologies, Inc., Berry Genetics, Inc., BGI Genomics Co., Ltd., Eurofins Scientific Services Limited, F. Hoffmann-La Roche Ltd, GE Healthcare, Igenomix, Illumina Inc., Laboratory Corporation, Natera Inc., PerkinElmer Inc., Thermo Fisher Scientific Inc., and Yourgene Health plc.

Key Questions Answered in This Report

• 1. What was the size of the global non-invasive prenatal testing market in 2023?
• 2. What is the expected growth rate of the global non-invasive prenatal testing market during 2024-2032?
• 3. What are the key factors driving the global non-invasive prenatal testing market?
• 4. What has been the impact of COVID-19 on the global non-invasive prenatal testing market?
• 5. What is the breakup of the global non-invasive prenatal testing market based on the product type?
• 6. What is the breakup of the global non-invasive prenatal testing market based on the test type?
• 7. What is the breakup of the global non-invasive prenatal testing market based on the technology?
• 8. What is the breakup of the global non-invasive prenatal testing market based on the method?
• 9. What is the breakup of the global non-invasive prenatal testing market based on the application?
• 10. What is the breakup of the global non-invasive prenatal testing market based on the end-user?
• 11. What are the key regions in the global non-invasive prenatal testing market?
• 12. Who are the key companies/players in the global non-invasive prenatal testing market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Non-Invasive Prenatal Testing Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product Type

• 6.1 Consumables
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Instruments
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Test Type

• 7.1 Materni 21
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Harmony
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Panaroma
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Verifi
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 NIFTY
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Others
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast

8 Market Breakup by Technology

• 8.1 NGS
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 WGS
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Method

• 9.1 Ultrasound Detection
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Biochemical Screening Tests
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Cell-Free DNA in Maternal Plasma Tests
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Fetal Cells in Maternal Blood Tests
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast
• 9.5 Others
  • 9.5.1 Market Trends
  • 9.5.2 Market Forecast

10 Market Breakup by Application

• 10.1 Trisomy
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Microdeletion Syndrome
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Others
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast

11 Market Breakup by End-User

• 11.1 Hospitals
  • 11.1.1 Market Trends
  • 11.1.2 Market Forecast
• 11.2 Diagnostic Laboratories
  • 11.2.1 Market Trends
  • 11.2.2 Market Forecast
• 11.3 Others
  • 11.3.1 Market Trends
  • 11.3.2 Market Forecast

12 Market Breakup by Region

• 12.1 North America
  • 12.1.1 United States
    • 12.1.1.1 Market Trends
    • 12.1.1.2 Market Forecast
  • 12.1.2 Canada
    • 12.1.2.1 Market Trends
    • 12.1.2.2 Market Forecast
• 12.2 Asia Pacific
  • 12.2.1 China
    • 12.2.1.1 Market Trends
    • 12.2.1.2 Market Forecast
  • 12.2.2 Japan
    • 12.2.2.1 Market Trends
    • 12.2.2.2 Market Forecast
  • 12.2.3 India
    • 12.2.3.1 Market Trends
    • 12.2.3.2 Market Forecast
  • 12.2.4 South Korea
    • 12.2.4.1 Market Trends
    • 12.2.4.2 Market Forecast
  • 12.2.5 Australia
    • 12.2.5.1 Market Trends
    • 12.2.5.2 Market Forecast
  • 12.2.6 Indonesia
    • 12.2.6.1 Market Trends
    • 12.2.6.2 Market Forecast
  • 12.2.7 Others
    • 12.2.7.1 Market Trends
    • 12.2.7.2 Market Forecast
• 12.3 Europe
  • 12.3.1 Germany
    • 12.3.1.1 Market Trends
    • 12.3.1.2 Market Forecast
  • 12.3.2 France
    • 12.3.2.1 Market Trends
    • 12.3.2.2 Market Forecast
  • 12.3.3 United Kingdom
    • 12.3.3.1 Market Trends
    • 12.3.3.2 Market Forecast
  • 12.3.4 Italy
    • 12.3.4.1 Market Trends
    • 12.3.4.2 Market Forecast
  • 12.3.5 Spain
    • 12.3.5.1 Market Trends
    • 12.3.5.2 Market Forecast
  • 12.3.6 Russia
    • 12.3.6.1 Market Trends
    • 12.3.6.2 Market Forecast
  • 12.3.7 Others
    • 12.3.7.1 Market Trends
    • 12.3.7.2 Market Forecast
• 12.4 Latin America
  • 12.4.1 Brazil
    • 12.4.1.1 Market Trends
    • 12.4.1.2 Market Forecast
  • 12.4.2 Mexico
    • 12.4.2.1 Market Trends
    • 12.4.2.2 Market Forecast
  • 12.4.3 Others
    • 12.4.3.1 Market Trends
    • 12.4.3.2 Market Forecast
• 12.5 Middle East and Africa
  • 12.5.1 Market Trends
  • 12.5.2 Market Breakup by Country
  • 12.5.3 Market Forecast

13 SWOT Analysis

• 13.1 Overview
• 13.2 Strengths
• 13.3 Weaknesses
• 13.4 Opportunities
• 13.5 Threats

14 Value Chain Analysis

15 Porters Five Forces Analysis

• 15.1 Overview
• 15.2 Bargaining Power of Buyers
• 15.3 Bargaining Power of Suppliers
• 15.4 Degree of Competition
• 15.5 Threat of New Entrants
• 15.6 Threat of Substitutes

16 Competitive Landscape

• 16.1 Market Structure
• 16.2 Key Players
• 16.3 Profiles of Key Players
  • 16.3.1 Agilent Technologies, Inc.
    • 16.3.1.1 Company Overview
    • 16.3.1.2 Product Portfolio
    • 16.3.1.3 Financials
    • 16.3.1.4 SWOT Analysis
  • 16.3.2 Berry Genetics Inc.
    • 16.3.2.1 Company Overview
    • 16.3.2.2 Product Portfolio
  • 16.3.3 BGI Genomics Co. Ltd.
    • 16.3.3.1 Company Overview
    • 16.3.3.2 Product Portfolio
    • 16.3.3.3 Financials
  • 16.3.4 Eurofins Scientific Services Limited
    • 16.3.4.1 Company Overview
    • 16.3.4.2 Product Portfolio
    • 16.3.4.3 Financials
  • 16.3.5 F. Hoffmann-La Roche Ltd
    • 16.3.5.1 Company Overview
    • 16.3.5.2 Product Portfolio
    • 16.3.5.3 SWOT Analysis
  • 16.3.6 GE Healthcare
    • 16.3.6.1 Company Overview
    • 16.3.6.2 Product Portfolio
  • 16.3.7 Igenomix
    • 16.3.7.1 Company. Overview
    • 16.3.7.2 Product Portfolio
    • 16.3.7.3 Financials
  • 16.3.8 Illumina Inc.
    • 16.3.8.1 Company Overview
    • 16.3.8.2 Product Portfolio
    • 16.3.8.3 Financials
    • 16.3.8.4 SWOT Analysis
  • 16.3.9 Laboratory Corporation
    • 16.3.9.1 Company Overview
    • 16.3.9.2 Product Portfolio
    • 16.3.9.3 Financials
    • 16.3.9.4 SWOT Analysis
  • 16.3.10 Natera Inc.
    • 16.3.10.1 Company Overview
    • 16.3.10.2 Product Portfolio
    • 16.3.10.3 Financials
  • 16.3.11 Perkinelmer Inc.
    • 16.3.11.1 Company Overview
    • 16.3.11.2 Product Portfolio
    • 16.3.11.3 Financials
    • 16.3.11.4 SWOT Analysis
  • 16.3.12 Thermo Fisher Scientific Inc.
    • 16.3.12.1 Company Overview
    • 16.3.12.2 Product Portfolio
    • 16.3.12.3 Financials
    • 16.3.12.4 SWOT Analysis
  • 16.3.13 Yourgene Health plc
    • 16.3.13.1 Company Overview
    • 16.3.13.2 Product Portfolio
    • 16.3.13.3 Financials